Table 1.
Clinicopathological and serological data of the patients of the study.
| Normals | Chronic HBV hepatitis |
Chronic HCV hepatitis |
NAFLDa | Autoimmune diseasesb | MTX-related toxicityc | ||
|---|---|---|---|---|---|---|---|
| Diagnosis | Relapse | ||||||
| No. | 8 | 19 | 7 | 14 | 11 | 8 | 2 |
| Sex (M/F)d | 5/3 | 9/10 | 4/3 | 11/3 | 6/5 | 2/6 | 0/2 |
| Age (years) (mean, range) | 53.3 (27–67) | 49.3 (24–64) | 48.6 (22–65) | 39.6 (27–50) | 41.9 (21–66) | 56.8 (37–73) | 66 (60–72) |
| AST (U/μL)e (mean, range) | 46.6 (42–56) | 185 (17–1969) | 76.6 (31–277) | 69.5 (24–218) | 34.9 (19–63) | 66.5 (30–225) | 32.5 (24–41) |
| ALT (U/μL)f (mean, range) | 55 (48–70) | 193 (15–1478) | 102 (32–332) | 91.2 (32–213) | 58.8 (15–141) | 65.5 (31–212) | 28.5 (17–40) |
|
| |||||||
| Inflammation gradeg | |||||||
| I-0 | 8 | — | — | — | 3 | — | — |
| I-1 | — | 4 | — | 2 | 3 | — | 2 |
| I-2 | — | 8 | 6 | 6 | 5 | — | — |
| I-3 | — | 5 | 1 | 6 | — | 3 | — |
| I-4 | — | 2 | — | — | — | 1 | — |
|
| |||||||
| Fibrosisg (mean, range) | 0 | 3.4 (0–6) | 3.4 (1–5) | 2.3 (1–4) | 0.5 (0–2) | 2.8 (0–6) | 1 (1–1) |
| HAI score (mean, range) | 7.52 (1–15) | 7.57 (5–11) | 7.21 (2–12) | ||||
| Viral load (mean, range) | 79.8 Meq/mL (<0.01–21) | 6.39 Meq/mL (<0.01–4.5) | 1.16 × 106 IU/mL (0.06–6.2) | ||||
aNAFLD: nonalcoholic fatty liver disease; bautoimmune diseases refers to autoimmune hepatitis (4 patients) and primary biliary cirrhosis (4 patients); cMTX: methotrexate; dM: male; F: female; eAST: aspartate aminotransferase; fALT: alanine aminotransferase; ginflammation grade (I-0: without inflammation, I-1: minimal, I-2: mild, I-3: moderate, and I- 4: marked) and fibrosis stage were assessed as presented in Section 2.